These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


297 related items for PubMed ID: 7873647

  • 1. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.
    Schott ME, Frazier KA, Pollock DK, Verbanac KM.
    Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
    Wilbur DS, Stray JE, Hamlin DK, Curtis DK, Vessella RL.
    Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
    [Abstract] [Full Text] [Related]

  • 3. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J.
    Cancer Res; 1993 Aug 15; 53(16):3776-83. PubMed ID: 8339291
    [Abstract] [Full Text] [Related]

  • 4. A cross-linked monoclonal antibody fragment for improved tumor targeting.
    Stalteri MA, Mather SJ.
    Bioconjug Chem; 1995 Aug 15; 6(2):179-86. PubMed ID: 7599261
    [Abstract] [Full Text] [Related]

  • 5. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM.
    Bioconjug Chem; 2002 Aug 15; 13(5):1054-70. PubMed ID: 12236788
    [Abstract] [Full Text] [Related]

  • 6. Assessment of radiolabeled stabilized F(ab')2 fragments of monoclonal antiferritin in nude mouse model.
    Quadri SM, Lai J, Mohammadpour H, Vriesendorp HM, Williams JR.
    J Nucl Med; 1993 Dec 15; 34(12):2152-9. PubMed ID: 8254403
    [Abstract] [Full Text] [Related]

  • 7. Dextran modification of a Fab'--beta-lactamase conjugate modulated by variable pretreatment of Fab' with amine-blocking reagents.
    Mikolajczyk SD, Meyer DL, Fagnani R, Hagan MS, Law KL, Starling JJ.
    Bioconjug Chem; 1996 Dec 15; 7(1):150-8. PubMed ID: 8742004
    [Abstract] [Full Text] [Related]

  • 8. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
    Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Bouwman WH, van der Graaf WT, Oyen WJ, Boerman OC.
    Mol Pharm; 2012 Aug 06; 9(8):2314-21. PubMed ID: 22747077
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
    King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, Baldock D, Proudfoot KA, Lawson AD, Beeley NR.
    Cancer Res; 1994 Dec 01; 54(23):6176-85. PubMed ID: 7954464
    [Abstract] [Full Text] [Related]

  • 11. Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.
    Kan KS, Anderson VA, Leong WS, Smith AM, Worth AT, Stevenson GT.
    J Immunol; 2001 Jan 15; 166(2):1320-6. PubMed ID: 11145716
    [Abstract] [Full Text] [Related]

  • 12. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells.
    Khawli LA, Biela BH, Hu P, Epstein AL.
    Hybrid Hybridomics; 2002 Feb 15; 21(1):11-8. PubMed ID: 11991812
    [Abstract] [Full Text] [Related]

  • 13. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
    Peräalä-Heape M, Vihko P, Vihko R.
    Anticancer Res; 1991 Feb 15; 11(3):1327-31. PubMed ID: 1888168
    [Abstract] [Full Text] [Related]

  • 14. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
    Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF, Whitlow M, Snoy P, Schlom J.
    Cancer Res; 1991 Dec 01; 51(23 Pt 1):6363-71. PubMed ID: 1933899
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
    Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D.
    J Nucl Med; 1999 Sep 01; 40(9):1536-46. PubMed ID: 10492377
    [Abstract] [Full Text] [Related]

  • 16. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
    Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RH.
    Br J Cancer; 1996 Nov 01; 74(9):1397-405. PubMed ID: 8912535
    [Abstract] [Full Text] [Related]

  • 17. Biodistribution and tumor localization of 111In-labeled unmodified and modified F(ab')2 fragments of human monoclonal IgM (16.88) in a nude mouse model.
    Quadri SM, Siddiqui A, Klein JL, Vriesendorp HM.
    Nucl Med Biol; 1995 May 01; 22(4):413-23. PubMed ID: 7550017
    [Abstract] [Full Text] [Related]

  • 18. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
    Siegall CB, Gawlak SL, Chin JJ, Zoeckler ME, Kadow KF, Brown JP, Braslawsky GR.
    Bioconjug Chem; 1992 May 01; 3(4):302-7. PubMed ID: 1390985
    [Abstract] [Full Text] [Related]

  • 19. The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.
    Leung SO, Qu Z, Hansen HJ, Shih LB, Wang J, Losman MJ, Goldenberg DM, Sharkey RM.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3106s-3117s. PubMed ID: 10541351
    [Abstract] [Full Text] [Related]

  • 20.
    Cheng KT.
    ; 2004 Oct 01. PubMed ID: 20641775
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.